Biologic treatment costs for plaque psoriasis more than doubled from 2007 to 2021, despite cheaper alternatives. Switching to the lowest-cost biologic in each class could reduce treatment costs by ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

The trial enrolled patients aged 12 years and older whose specific skin sites were affected by plaque psoriasis of at least moderate severity. The data were part of a presentation at the ongoing ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis ... plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and soles of the feet.

I broke out in guttate, inverse, and plaque psoriasis from head to toe. It lasted for seven months. For those seven months, I didn’t feel like myself. The pain was constant. I couldn’t be ...

This can be the case for those living with moderate to severe plaque psoriasis, an immune condition that causes dry, itchy and scaly patches (or plaques) to form across the skin 1 and that affects ...

The phase 3 ICONIC-TOTAL trial has been evaluating the drug in adults and adolescents aged 12 years and older with at least moderate plaque psoriasis affecting high-impact skin sites. It is estimated ...

China’s National Medical Products Administration has given the thumbs up to Akeso Pharmaceuticals Inc.’s ebdarokimab for treating moderate to severe plaque psoriasis in adults. An interleukin ...

Icotrokinra is the first investigational, oral peptide designed to selectively block interleukin-23 receptors in people with moderate to severe plaque psoriasis, ulcerative colitis and other ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Ebdarokimab was evaluated in five clinical studies involving Chinese patients with moderate-to-severe plaque psoriasis. Two pivotal Phase III studies demonstrated ebdarokimab's efficacy and safety ...